1.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODY...
by Kereiakes, Dean J., MD, FACC, FSCAI
The American heart journal, 2015, Vol.169 (6), p.906-915.e13
2.
Acute Coronary Syndromes: Diagnosis and Management, Part I
by Kumar, Amit, MD
Mayo Clinic proceedings, 2009, Vol.84 (10), p.917-938
3.
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline character...
by James, Stefan, MD
The American heart journal, 2009, Vol.157 (4), p.599-605
4.
In-Hospital Major Bleeding During ST-Elevation and Non–ST-Elevation Myocardial Infarction Care: Derivation and Validation of a Model from the ACTION Registry®-GWTG
by Mathews, Robin, MD
The American journal of cardiology, 2011, Vol.107 (8), p.1136-1143
5.
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on card...
by Cannon, Christopher P., MD
The American heart journal, 2008, Vol.156 (5), p.826-832
6.
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPRO...
by Blazing, Michael A., MD
The American heart journal, 2014, Vol.168 (2), p.205-212.e1
7.
Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines
by Sachdeva, Amit, MD
The American heart journal, 2009, Vol.157 (1), p.111-117.e2
8.
Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: The Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registr...
by Chin, Chee Tang, MBChB
The American heart journal, 2011, Vol.161 (1), p.113-122.e2
9.
Mixed Dyslipidemia, Metabolic Syndrome, Diabetes Mellitus, and Cardiovascular Disease: Clinical Implications
by Cannon, Christopher P., MD
The American journal of cardiology, 2008, Vol.102 (12), p.5L-9L
10.
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Art...
by Laine, Loren, Prof
The Lancet (British edition), 2007, Vol.369 (9560), p.465-473
11.
Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrom...
by O'Donoghue, Michelle L., MD, MPH
The American heart journal, 2011, Vol.162 (4), p.613-619.e1
12.
Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With...
by Gotto, Antonio M., MD, DPhil
The American journal of cardiology, 2014, Vol.113 (1), p.76-83
13.
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versu...
by White, Harvey, DSc, FCSANZ
The American heart journal, 2010, Vol.160 (4), p.655-661.e2
14.
An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design
by Califf, Robert M., MD
The American heart journal, 2010, Vol.159 (5), p.705-709
15.
Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines–Corona...
by Deedwania, Prakash, MD
The American heart journal, 2017, Vol.187, p.78-87
16.
Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function Sub...
by Storey, Robert F., MD
The American journal of cardiology, 2011, Vol.108 (11), p.1542-1546
17.
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS tria...
by Price, Matthew J., MD
The American heart journal, 2009, Vol.157 (5), p.818-824.e1
18.
Ethnic Differences in Cardiovascular Risks and Mortality in Atherothrombotic Disease: Insights From the REduction of Atherothrombosis for Continued Health (REACH) Registry
by Meadows, Telly A., MD
Mayo Clinic proceedings, 2011, Vol.86 (10), p.960-967
19.
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infect...
by Morrow, David A., MD, MPH
The American heart journal, 2008, Vol.155 (1), p.49-55
20.
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non–ST-segment elevation myocardial infarction
by Pokorney, Sean D., MD, MBA
The American heart journal, 2015, Vol.171 (1), p.25-32
